Přeskočit na horní lištu
Přeskočit na hlavičku
Přeskočit na obsah
Přeskočit na patičku
EN
>
Publikace
>
Vyhledávání publikací
Vyhledávání publikací
Pokročilé vyhledávání
Repozitář
Vybrané publikace/výsledky
MikroRNA v onkologii (2012)
Úloha microRNA v regulaci signalizace přes b-buněčný receptor a jejich vztah k patogenezi chronické lymfocytární leukémie (CLL) (2012)
Microrna-34a as a marker for fludarabine resistance and impairment of p53-pathway in chronic lymphocytic leukemia (2012)
The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus (2013)
The expression of a single microRNA -miR-34a - is a reliable marker for impairment of TP53-pathway in chronic lymphocytic leukemia (2013)
The expression of micrRNA-34a is a highly reliable for impairment of p53-pathway in CLL: development of clinically applicable assay (2013)
Biological and clinical relevance of mirnas induced in chronic lymphocytic leukemia (CLL) cells during administration of therapy in vivo and in vitro (2014)
Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia (2014)
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach (2014)
MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. (2014)
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia (2015)
miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 (2014)
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells (2015)
MicroRNAs in B cell lymphomas: how a complex biology gets more complex (2015)
MicroRNA miR-150 regulates B-cell receptor signaling (BCR) and disease aggressiveness in chronic lymphocytic leukemia (2014)
Identification of microRNAs involved in DNA damage response in malignant B cells and their biological and clinical relevance (2014)
Identification of microRNAs involved in DNA damage response in malignant B cells and their biological and clinical relevance (2014)
Identifikace MicroRNAs zapojených do reakce na poškození DNA v maligních B lymfocytech a jejich biologická a klinická relevance (2014)
Identification of microRNAs involved in DNA damage response in malignant B cells and their biological and clinical relevance (2014)
MicroRNAs in Embryonic Stem Cells (2015)
DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: The same outcome of treatment with different doses in sensitive cell lines (2015)
Regulation of microRNA expression based on their common factors and properties (2015)
Regulation of microRNA expression based on their common factors and properties (2015)
Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study (2015)
miRNome-wide regulation of microRNA expression (2015)
Mutations in the TP53 gene show features of somatic hypermutation process with prominent difference between IGHV mutated and unmutated chronic lymphocytic leukemia (2015)
MicroRNA-150 influences microenvironmental interactions and prognosis of follicular lymphoma (2015)
MicroRNA-150 influences microenvironmental interactions and prognosis of B cell malignancies. (2015)
MicroRNAs in DNA damage response and BCR signaling in malignant B cells. (2015)
MicroRNA involvement in DNA damage response and BCR signaling in malignant B cells (2015)
MicroRNA-150 influences microenvironmental interactions and prognosis of B cell malignancies (2015)
The effect of ZAP-70 on adaptor molecule involved in microenvironmental interactions of malignant B cells (2015)
Focal adhesion kinase regulation and expression in malignant B cells (2015)
Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database (2016)
Microenvironmental interactions up-regulate CD20 expressionin CLL B cells, but confer resistance to rituximab (2015)
Interakce buněk CLL s mikroprostředím vede ke zvýšené expresi CD20 přes chemokinovou dráhu CXCR4/SDF-1: Implikace pro léčbu anti-CD20 protilátkami a BCR-inhibitory. (2015)
p53 function tests in relation to TP53 gene aberrations (2015)
Microenvironmental interactions up-regulate CD20 expression in CLL B cells through the CXCR4/SDF-1 axis: implications for CD20-targeting antibodies and the use of BCR-inhibitors in combination. (2015)
The role of microRNA in cell cycle regulation and differetiation of human embryonic stem cell-derived neural stem cells (2015)
Porovnání výsledků genové exprese pří použití různých anotací genomu (2016)
The role of microRNA and HMGB proteins in cell cycle regulation and differentiation of human embryonic stem cell-derived neural stem cells (2015)
Způsob absolutní kvantifikace exprese miRNA, zejména miR-34a a/nebo miR-150, a jeho použití v diagnostice a prognostice B-buněčných malignit (2016)
THE IMPROVING OUTCOME OF NON-HODGKIN LYMPHOMA (NHL) WITHIN 15 YEARS PERIOD-REAL WORLD DATA OF NATIONAL-WIDE LYMPHOMA PROJECT (2016)
Identification of miRNA expression profiles in human mesial temporal lobe epilepsy with hippocampal sclerosis (2016)
Whole miRNome Sequencing of Human Epileptic Brain Tissue (2016)
Exprese CD20 je regulována interakcí CLL buněk s mikroprostředím a rituximab preferenčně eliminuje maligní B buňky s vysoce aktivní signalizací přes B‐buněčný receptor (2016)
Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis (2016)
MicroRNAs in the microenvironmental interactions of B cell leukemias. (2016)
The expression of CD20 on malignant B cells is regulated by chemokine signaling through the CXCR4/SDF1 axis: implications for targeting the microenvironmental interactions. (2016)
Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis. (2016)
Molecular activity in follicular lymphoma monitored by BCL2/IGH in the peripheral blood. The old story in a new light? (2016)
Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 AXIS. (2016)
Úloha microRNA-150 v prognóze a transformaci folikulárního lymfomu. (2016)
Interakce B lymfocytů s mikroprostředím vedou ke zvýšené expresi CD20 přes aktivaci dráhy CXCR4/SDF-1: význam pro léčbu pacientů s B buněčnou leukémií. (2016)
Rituximab preferentially eliminates BCR signaling proficient chronic lymphocytic leukemia B cells In Vivo (2016)
The role of microRNA-150 in the prognosis and transformation of follicular lymphoma. (2016)
Introduction of nanopore sequencing to genomic core facility RNA workflows (2016)
The biology of microRNAs and how to move this into clincal trials in hematological malignancies (2016)
Biologické aspekty FL a transformace (2016)
Nové poznatky o patogenezi B buněčných malignit a cesty k cílené léčbě. (2016)
Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry (2016)
Hodnocení klinického stadia a léčebné odpovědi u maligních lymfomů – doporučení Kooperativní lymfomové skupiny na základě revidovaných kritérií z roku 2014 (Luganská klasifikace) (2016)
miRNA profile of mesial temporal lobe epilepsy (2017)
Význam deregulace mikroRNA v molekulární patogenezi a histologické transformaci folikulárního lymfomu (2017)
The complexity of BCR signaling in CLL and other B cell malignancies: from the basic science to clinical applications. (2017)
Dopad rekurentních mutací na dobu do progrese po terapiích zahrnujících rituximab v 1. linii u pacientů s CLL. (2017)
Comparative analysis of miRNA profiles in human patients with epilepsy and animal models (2017)
The impact of choice of reference gene annotation (2017)
Regulation of B-cell receptor signalling in chronic lymphocytic leukaemia (CLL) microenvironment via modulation of GAB1 protein levels. (2017)
Význam deregulace mikroRNA v molekulární patogenezi a histologické transformaci folikulárního lymfomu (2017)
The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies (2017)
Nové poznatky o patogenezi folikulárního lymfomu a koncepty cílené léčby (2017)
Comparative analysis of miRNA profiles in human patients with epilepsy and animal model (2017)
MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole miRNome profiling of human hippocampus (2017)
Nové poznatky o mikroprostředí a BCR signalizaci u CLL a lymfomů. Implikace pro cílenou léčbu a terapeutickou rezistenci. (2017)
BCR signalling proficient chronic lymphocytic leukaemia cells are prone to rituximab mediated elimination in vivo. (2017)
Differential expression of microRNAs in transformation of follicular lymphoma to diffuse large B cell lymphoma (2017)
Down-regulation of miR-150 and up-regulation of its target FOXP1 is associated with transformation of follicular lymphoma. (2017)
The role of microenvironment in the regulation of B-cell receptor signalling via modulation of GAB1 protein levels (2017)
MicroRNA induced by DNA damage response regulate the expression of FOXP1 and therapy response in CLL (2017)
Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients (2017)
MicroRNA induced by DNA damage response regulates the expression of FOXP1 and therapy response in CLL (2017)
MicroRNAs and BCR signalling in CLL. (2017)
Impact of recurrent mutations on progression-free survival in CLL patients treated with front line rituximab-based regimens. (2017)
Buněčná biologie folikulárního lymfomu (2017)
The expression of T-cell specific microRNA associates with the transformation of indolent follicular lymphoma to agressive lymphomas (2018)
Transformace folikulárního lymfomu (2018)
MYC-mediated downregulation of miR-150 contributes to the transformation of follicular lymphoma to DLBCL by upregulating FOXP1 levels (2018)
CD20 supports BCR signaling in an intra clonal aggressive chronic lymphocytic leukemia subpopulation of cells and rituximab primarily targets these BCR proficient B cells in vivo (2018)
MYC-mediated downregulation of miR-150 contributes to the transformation of follicular lymphoma by upregulating FOXP1 levels (2018)
Inovativní inhibitor proteinu CHK1 indukuje apoptózu u buněk chronické lymfocytární leukémie s mutacemi v genu TP53 (2018)
CD20 reguluje signalizaci přes B-buněčný receptor v mikroprostředí chronické lymfocytární leukémie (2018)
CD20 is a direct regulator of B-cell receptor signaling in the microenvironment of chronic lymphocytic leukemia (2018)
Genetické aberace a doba do progrese onemocnění u pacientů s CLL léčených režimy FCR nebo BR v 1. linii (2018)
Selective CHK1 inhibitor MU380 exhibits single-agent activity against chronic lymphocytic leukemia cells with TP53 mutations (2018)
Genetic aberrations and progression-free survival in CLL patients treated with front line rituximab-based chemoimmunotherapy (FCR/BR): clinical practice experience (2018)
The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study (2018)
Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels (2018)
microRNA – are you real? (2018)
microRNA – are you real? (2018)
The surprises in B cell receptor signalling regulation: from basic biology to therapeutic implications in B cell malignancies (2018)
Překvapivé mechanismy regulace signalizace B buněčného receptoru (BCR): od mechanismů k terapii B buněčných malignit (2018)
Microenvironmental interactions in malignant B cells: from biological mechanisms to better targeted therapies (2018)
Microenvironmental interactions in malignant B cells: from biological mechanisms to better targeted therapies (2018)
Microenvironmental interactions in mature B cell malignancies: combinatorial strategies of targeted therapy (2018)
MicroRNAs contribute to high-grade transformation of follicular lymphoma (2018)
New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs (2018)
miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels (2018)
MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells (2019)
Bioinformatic analysis of microRNAs and long non-coding RNAs in malignant B cells (2018)
p53 limits B cell receptor (BCR) signalling: a new role for miR-34a and FOXP1 (2018)
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience (2019)
Detection of a deletion at 22q11 locus involving ZNF280A/ZNF280B/PRAME/GGTLC2 in B-cell malignancies: simply a consequence of an immunoglobulin lambda light chain rearrangement (2019)
Oct4-mediated reprogramming induces embryonic-like microRNA expression signatures in human fibroblasts (2019)
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells (2019)
Potenciál inhibice proteinu CHK1 u chronické lymfocytární leukemie s mutacemi v genu TP53 (2019)
Mechanism of leukemia cell adaptation to targeted therapy in chronic lymphocytic leukemia (2019)
High surface tumor IgM levels associate with reduced response duration and with BTK bypass during ibrutinib therapy in CLL patients (2019)
Regulation of B Cell Receptor signalling in B cell leukemias: novel mechanisms and therapeutic implications. (2019)
The surprising role of microRNAs in the DNA damage and B cell receptor signalling in malignant B cells (2019)
Potenciál inhibice proteinu checkpoint kinase 1 u chronické lymfocytární leukémie s mutacemi v genu TP53. (2019)
MicroRNA a regulace BCR signalizace u B buněčných malignit: Biomarkery a terapeutické implikace. (2019)
The role of MYC in the transformation and aggressiveness of ?indolent? B-cell malignancies (2020)
Komplexní mechanismy účinku inhibitorů „BCR signalizace“ a vzniku rezistence na tuto cílenou léčbu u chronické lymfocytární leukemie (2019)
Nové mechanismy regulace B buněčné signalizace u leukémií a lymfomů. (2019)
B Cell Receptor Signalling Regulation by Non-coding RNAs. (2019)
CD20 in the context of microenvironmental interactions of malignant B cells: Implications for targeted therapy. (2019)
Překvapivá role micro RNA v odpovědi na poškození DNA a regulaci BCR signalizace u CLL. (2019)
Jak vlastně fungují anti CD 20 monoklonální protilátky? Víme více po 20 letech jejich používání? (2019)
The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology (2020)
High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade During Ibrutinib Therapy in Patients with CLL. (2019)
The Impact of Regulatory RNA Molecules. (2019)
Analysis of Mutational Landscape in Systemic Anaplastic Large Cell Lymphoma Identifies Novel Prognostic Markers. (2019)
Peripheral blood of CLL patients is repopulated with complement resistant malignant cells one day after rituximab infusion: possible implications for subsequent chemotherapy. (2019)
Hypoxia/Hif1 Alpha prevents premature neuronal differentiation of neural stem cells through the activation of Hes1 (2020)
The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy (2020)
mir-29 influences CD40 signaling in chronic lymphocytic leukemia (CLL) (2020)
Analysis mutational landscape in systemic anaplastic large cell lymphoma identifies novel prognostic markers (2020)
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies (2020)
LncRNAs in adaptive immunity: role in physiological and pathological conditions (2021)
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors (2021)
Laboratorní analýza odpovědí na cílenou léčbu u CLL: jen vědecká obsese nebo cesta k průlomové léčbě? (2020)
ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias (2020)
Mutational landscape analysis in systematic anaplastic large cell lymphoma identifies novel prognostic markers. (2020)
mir-29 regulates the CD40 signaling in the microenvironment of chronic lymphocytic leukemia. (2020)
Development of novel patient-derived xenograft model of chronic lymphocytic leukemia. (2020)
Regulation of BCR signaling during therapy in chronic lymphocytic leukemia. (2020)
Pokroky v pochopení patogeneze FL a jejich implikace pro léčbu. (2020)
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma (2021)
microRNA – are you real?! (2018)
RNA-seq Characterization of Melanoma Phenotype Switch in 3D Collagen after p38 MAPK Inhibitor Treatment (2021)
GAB1 Regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia: novel therapeutic target (2021)
PI3KD inhibitor idelalisib snižuje hladiny CD20 u chronické lymfocytární leukémie inhibicí IL4-STAT6 signální dráhy. (2021)
Duplikace 8q24 v chronické lymfocytární leukémii: Cytogentická a molekulárně-biologická analýza aberací genu MYC. (2021)
Patogeneze CLL a vztah k cílené léčbě (2021)
GAB1 reguluje tonickou AKT signalizaci a migraci buněk chronické lymfatické leukémie: implikace pro kombinační léčbu s BCR inhibitory. (2021)
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K delta inhibitor idelalisib (2021)
FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia (2021)
FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia: Novel Therapeutic Target. (2021)
IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3Kδ Inhibitor Idelalisib. (2021)
GAB1 – novel regulator of migration capacity and tonic AKT activity in CLL: Implications for combinatorial therapy with BCR inhibitors. (2021)
Ibrutinib Blocks CD40 Signalling in CLL in Vivo by Reducing TRAF4 Levels. (2021)
Microenvironmental interactions in B cell leukemias and lymphomas: Implications for targeted therapy. (2021)
Patient-derived Xenograft Model of Chronic Lymphocytic Leukaemia Based on Mimicking Its Microenvironment. (2021)
The role of long non-coding RNAs in the BCR-mediated activation of malignant B cells. (2021)
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR. (2021)
MicroRNAs in the regulation of microenvironmental interactions of malignant B cells. (2021)
miR-29-TRAF4 axis is a novel regulator of CD40 signaling in malignant B cells. (2021)
miR-29 influences CD40 signaling in chronic lymphocytic leukemia (CLL): and axis affected by BCR inhibitors. (2021)
The biology of miRNAs in B cell malignancies and their use as biomarkers. (2021)
Ibrutinib blocks CD40 signalling in malignant B cells by reducing TRAF4 levels. (2021)
Název: The role of microRNA and protein-coding genes in the biology of neural stem cells. (2021)
Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion (2021)
Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides (2022)
In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing (2022)
Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations (2022)
IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib. (2022)
Sekvenování dlouhých nekódujících RNA v exozomech u pacientů s kolorektálním karcinomem (2022)
The role of long non-coding RNAs in BCR-mediated CLL activation. (2022)
Versatile coculture systém to study chronic lymhocytic leukemia proliferation. (2022)
The role of long non-coding RNAs in the microenvironmental interactions of malignant B cells. (2022)
Adaptace buněk chronické lymfocytární leukémie na cílenou léčbu BCR inhibitory. (2022)
Modelling chronic lymphocytic leukaemia microenvironment. (2022)
High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL (2022)
Genetic mechanism for the loss of PRAME in B cell lymphomas (2022)
GAB1 as novel therapeutic target in B lymphoid and myeloid malignancies (2022)
Diagnostická sada pro stanoveni prognózy folikulárního lymfomu s pomocí kvantifikace miRNA (2022)
Acute myeloid leukemia suppression by palbociclib and ponatinib in patient-derived xenograft. (2023)
Způsob stanovení prognózy u pacientů s folikulárním lymfomem (2023)
MicroRNA Profiling of Self-Renewing Human Neural Stem Cells Reveals Novel Sets of Differentially Expressed microRNAs During Neural Differentiation In Vitro (2023)
Characterisation of Macrophage Response to Nickel Nanoparticles and Ions Released from Biomaterials (2023)
FOXO1-RICTOR AXIS induces adaptive increase in AKT activity during BCR inhibitor therapy in CLL: Implications for combination therapy. (2023)
Mechanismy adaptace CLL buněk na léčbu BCR inhibitory. (2023)
FOX01-rictor AXIS induces AKT phosporylation during CLL cell adaptation to BCR inhibitors: Implications for combinatorial therapy. (2023)
CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy (2023)
The role of casein kinase 1 inhibition in treatment of chronic lymphocytic leukemia. (2023)
Biomaterial selection does not affect AML engraftment in humanized ossicles. (2023)
Using a human pluripotent stem cell-based model to study the Alzheimer's disease pathogenesis in vitro (2022)
Transformace indolentního folikulární lymfomu v difuzní velkobuněčný B-lymfom – molekulární podstata „nádorové agresivity“ (2023)
Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genomewide CRISPR screening. (2023)
Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation. (2023)
Transcription factor FoxO1 Mediates Adaptive Increase in Akt Activity and Cell Survival During BCR Inhibitor Therapy in CLL. (2023)
The role of long non-coding RNAs in the microenvironmental interactions of malignant B cells. (2023)
On the role of long non-coding RNA in BCR signaling regulation in chronic lymphocytic leukemia. (2023)
Genome-wide CRISPR/Cas9 knockout screening revealed genes involved in CD20 regulation in rituximab-resistant cells. (2023)
Foxo1-Rictor axis mediates adaptive increase in Akt activity and cell survival during BCR inhibitor therapy in chronic lymphocytic leukemia. (2023)
Inhibitors for treatment of hematological malignancies (2023)
The role of long non-coding RNAs in the microenvironmental interactions of malignant B cells. (2023)
The role of long non-coding RNAs in BCR-mediated CLL activation. (2023)
Coculture model with CD40L, IL4 and IL21 for study chronic lymphocytic leukemia proliferation. (2023)
Nekódující RNA v biologii maligních B lymfocytů. (2023)
Transkripční faktor FoxO1 v adaptaci chronické lymfocytární leukémie na cílenou léčbu. (2023)
Molecular response of chronic lymphocytic leukemia cells to targeted therapy. (2023)
Inhibition of acute myeloid leukemia using palbociclib and ponatinib in a patient-derived xenograft model. (2023)
5′-UTR mRNA splicing determines CD20 levels (2023)
Functional analysis of LDLR variants using flow cytometry (2023)
Functional analysis of LDLR variants using flow cytometry and western blot (2023)
Blockage of BCL-XL overcomes venetoclax resistance across BCL2-positive lymphoid malignancies irrespective of BIM status (2024)
Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drug (2024)
Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities (2024)
FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia (2024)
FoxO1 signaling in B cell malignancies and its therapeutic targeting. (2024)
STROMAL CELLS ENGINEERED TO EXPRESS T CELL FACTORS INDUCE ROBUST CLL CELL PROLIFERATION IN VITRO AND IN PDX COTRANSPLANTATIONS ALLOWING THE IDENTIFICATION OF ANTI-PROLIFERATIVE DRUGS (2024)
Co-culture with CD40L, IL4 and IL21 expressing stromal cells induces robust CLL cell proliferation in vitro and in PDX co-transplantations (2024)
MOLECULAR MECHANISM OF NON-GENETIC ADAPTATION TO BTK INHIBITOR THERAPY IN CLL (2024)
Odebrat vše z výběru
Operace s vybranými výsledky
Export a tisk
Seznam vybraných záznamů
Další aplikace
Publikace
Informační systém
Přeskočit na horní lištuPřeskočit na hlavičkuPřeskočit na obsahPřeskočit na patičku
